Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to…
NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207
NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK,…
HKUST President Prof. Nancy IP Engages in Global Dialogues at Davos 2026 on Neuroscience, University Leadership, and the Future of Research
HONG KONG, Jan. 26, 2026 /PRNewswire/ -- Prof. Nancy IP, President of The…
New data reinforces Ipsens commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
14 abstracts will be presented across a range of neurological conditions including…
Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)
Patient insights informed the development of pilavapadin, Lexicon’s investigational, novel, non-opioid treatment…
